Patents by Inventor Matthias Machacek

Matthias Machacek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20250161444
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Therapeutic Inhibition of LPA Expression
    Publication number: 20250163415
    Abstract: The invention relates to the therapeutic inhibition of LPA gene expression, and in particular to effective doses and dosage regimes for the therapeutic use of the SLN360 molecule, in the prophylaxis or treatment of conditions associated with elevated levels of Lp(a). Such conditions include stroke, atherosclerosis, thrombosis, and cardiovascular diseases such as coronary heart disease and aortic stenosis.
    Type: Application
    Filed: February 8, 2023
    Publication date: May 22, 2025
    Inventors: David Rider, Daniel Swerdlow, Giles Camplon, Alison Scrimgeour, Curtis Rambaran, Rosamund Wilson, Matthias Machacek, Pascal Schulthess, James Wade
  • METHODS OF ADMINISTERING SECUKINUMAB
    Publication number: 20250161443
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20250161445
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • ACTRII ANTIBODY TREATMENTS
    Publication number: 20240368291
    Abstract: Provided herein are ActRII antibody dosage regimens, for the treatment of metabolic disorders, including obesity. In some embodiments, the dosage regimen is preceded by the administration of a loading dose of an ActRII antibody and can further optimize the efficacy of the treatment.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Inventors: Lloyd B. KLICKSTEIN, Matthias MACHACEK
  • COMBINATION THERAPIES
    Publication number: 20240325530
    Abstract: The disclosure relates to the combined use of an ActRII pathway agent, e.g., an ActRII receptor antibody, and a GLP-1 agonist for the treatment of metabolic disorders, including obesity. As provided herein, the combination treatment reduces fat mass and maintains or increases lean mass.
    Type: Application
    Filed: February 26, 2024
    Publication date: October 3, 2024
    Inventors: Lloyd Berl KLICKSTEIN, Matthias MACHACEK
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20230346926
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 2, 2022
    Publication date: November 2, 2023
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20230321231
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20230293683
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • Methods of treating ankylosing spondylitis using IL-17 antagonists
    Patent number: 11534491
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Methods of treating psoriasis using IL-17 antagonists
    Patent number: 11534490
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20220193234
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 8, 2021
    Publication date: June 23, 2022
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20210177966
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthiritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210162044
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20210128726
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: December 18, 2020
    Publication date: May 6, 2021
    Inventors: Shephard MPOFU, Hanno RICHARDS, Karthinathan THANGAVELU, Matthias MACHACEK
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20210113688
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
    Publication number: 20200276305
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: March 19, 2020
    Publication date: September 3, 2020
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20200171147
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 4, 2020
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Methods of treating psoriasis using IL-17 antibodies
    Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20190307880
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: June 12, 2019
    Publication date: October 10, 2019
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek